Advances in clinical applications of kisspeptin-GnRH pathway in female reproduction

In humans, all native kisspeptins (KP54, KP14, KP13, and KP10) share a typical C-terminal decapeptide sequence, enabling these peptides to bind to and activate KISS1R [9, 72]. Therefore, KP10 and KP54 are most commonly investigated in humans. While the reported half-life of KP54 varies from 28 min to 1.8 h in humans, it is clear that KP54 has a longer terminal half-life than KP10 in humans [73‐75]. Although Kotani et al. demonstrated that the bioactivity of KP54 and KP10 are equipotent and the two peptides bind to KISS1R with a similar affinity in humans [72, 76], KP54 is more suitable for bolus administration than KP10 in humans due to their pharmacokinetic properties. A bolus administration of KP54 can lead to a modest rise of LH levels at the follicular phase in healthy women, which does not happen after a bolus administration of KP10 [51] (Table 1). Additionally, the maximum LH rise is much more significant after a bolus administration of KP54 than after a similar dose of KP10 in healthy men [74, 77]. Their blood-brain barrier permeability explains the differentiation in biological activity in vivo between KP10 and KP54. Peripheral administration of KP54 can activate c-FOS in GnRH neurons behind the blood-brain barrier (BBB), but this is not seen after peripheral administration of KP10 [73]. Nevertheless, both KP54 and KP10 can elicit an endocrine response by activating kisspeptin receptors on GnRH neurons in the median eminence area, which is external to the BBB.

While KP54 is more stable and has a longer duration of action in vivo, KP10 has a shorter amino acid sequence and, therefore, is less expensive for manufacturers to produce analogs [73‐75]. Numerous kisspeptin analogs have been synthesized, including those containing substitutions with unnatural amino acids [78‐82]. Kisspeptins are susceptible to enzymatic proteolysis by matrix metalloproteinases (MMPs) at their Gly-Leu peptide bond in the C-terminal region [79, 83] (Fig. 4). Therefore, substituting these dipeptides may afford resistance to enzymatic degradation and maintain the KISS1R agonistic activity, such as (E)-Alkene- and hydroxyethylene-type isostere-containing analogs [78]. In another study, researchers designed and synthesized many KP10 analogs, among which the substitution of arginine at position 53, N(ω)(−)methylarginine analog 8 shows 3-fold more potent bioactivity than KP10, with trypsin cleavage resistance between positions 53 and 54 [85]. However, not all kisspeptin receptor agonists can maintain the in vivo efficacy with an increased in vitro stability. FTM080, a kisspeptin receptor agonist with a half-life of 6.6 hours in murine serum, is less effective in maintaining the duration of LH secretion in ewes than native KP10 [86]. Another KP10 analog, designed by the substitution of D-tyrosine for a tyrosine residue at position 1 ([dY](1)KP-10), binds to KISS1R with lower affinity than KP-10 and exhibits comparable bioactivity in vitro [87]. Interestingly, peripheral administration of [dY](1)KP-10 can increase plasma LH and testosterone more potently than KP-10 at 20 min postinjection in mice, indicating the affinity of kisspeptin analogs in vitro is not necessarily associated with their potency in vivo [87]. (Table 2).

KP10 analog C6 is designed by inserting an albumin-binding motif in the isoGlutamyl on the N-terminal amine to protect it from fast excretion and ω-methylation of arginine at position 9 to improve resistance to proteolytic degradation without affecting potency [89]. Additionally, the insertion of triazole between the leucine and the glycine may increase the lipophilicity and, therefore, membrane permeability of C6 [89]. Thus, C6 has a longer half-life in vivo than KP10 due to increased proteolytic stability [97]. Additionally, C6 is more potent than KP10, as demonstrated in ewes [89]. Electrophysiological recordings of GnRH neurons from murine brain slices demonstrate that C6 exerts a direct stimulatory action on GnRH neurons in the hypothalamus and induces ovulation, indicating a possible increase in lipophilicity of this molecule compared to KP10, at least in mice [89].

Compound 26 (C26) is a stable nonapeptide designed by the N-terminal truncation of KP10, and it has KISS1R binding affinities comparable to KP10 with improved serum stability [90, 91]. Continuous administration of C26 significantly suppresses testosterone in male rats, and the plasma testosterone levels following C26 treatment decreas faster than those receiving KP10 [90]. In addition, C26 can induce ovulation in female rats, indicating a possible increase in lipophilicity of this molecule compared to KP10, at least in rats [90].

TAK-448 and TAK 683 are two kisspeptin analogs designed bymodifying KP10 with nine amino acids [90, 98]. Compared with KP10, the two analogs show comparable KISS1R-binding affinity and potency with increased water solubility and half-life in vivo [92]. The two analogs are originally developed for clinical use in patients with prostate cancer due to kisspeptin’s ability to induce tachyphylaxis when given chronically at high doses [99, 100]. Inducing castrate levels of testosterone in vivo is beneficial intreating prostate cancer, in addition to kisspeptin’s putative antimetastatic activity [72]. A recent study evaluated the potency of TAK-448 (also known as MVT-602) to induce LH rise in the follicular phase of healthy women [67]. Despite the comparable half-life between TAK-448 and KP54, TAK-448 induces a prolonged duration of LH rise, though to a similar amplitude as KP54 [67], indicating that TAK-448 has increased resistance to degradation by proteosomes and can induce signals for a longer duration. In vitro experiments demonstrates that TAK-448 is more potent and induces a longer duration of GnRH neuronal firing than KP54 (115 vs. 55 min) [67].

Using alanine scanning and amino acid substitution, researchers found that Phe6, Arg9, and Phe10 residues lie on one face and constitute a binding pharmacophore of KP10, which is essential to the receptor binding [101]. Small molecules mimicking vital elements of this pharmacophore site can bind to and activate the kisspeptin receptor, albeit with reduced potency compared to KP10 [101]. RF9 (1-adamantane carbonyl-Arg-Phe-NH2) is an antagonist of receptors for the mammalian gonadotropin-inhibitory hormone receptor [102, 103]. Central administration of RF9 can induce a dose-dependent increase of gonadotropin levels in adult male and female rats and augment the gonadotropin-releasing effects of kisspeptin [102]. Interestingly, recent studies demonstrated that the stimulatory action of RF9 on gonadotropin release is mediated via direct KISS1R agonism, though the potency is slightly lower than KP10 in vitro [94, 95]. Additionally, RF9 can exert a dose-dependent excitatory action on brain slices of GnRH neurons in POA in adult male and diestrous female mice [94]. Another small molecule, benzoylated dipeptide Bz-Arg-Trp-NH2, shows promising KISS1R agonistic activity and better stability than the endogenous kisspeptins in rats. However, its selectivity towards other RFamide receptors such as NPFF1R and NPFF2R needs to be resolved [96]. Because the cost of synthesis and the stability of small molecules are more favorable than those of kisspeptin, it is worth investigating whether these small molecules can facilitate oral administration in the future and provide a therapeutic advantage in clinical trials. Additionally, more synthetic work is required to improve their selectivity toward KISS1R.

In addition to Phe6, Arg9, and Phe10, the amino acids residues Asn2 and Trp3 are also critical for receptor binding, and Tyr1 and Leu8 are necessary for receptor activation [84, 101, 104] (Fig. 4). Kisspeptin antagonism, P234, results from the substitution of Leu8 with d-Trp and of Ser5 with Gly, with further enhancement by the substitution of Tyr 1 with D-Ala [105]. P234 can bind to the kisspeptin receptor but can not induce signalings, which can induce around 90% inhibition of KP10 activated signalings in KISS1R-transfected CHO cells [105] (Table 3). While P234 inhibits kisspeptin-induced stimulation of GnRH/LH, the basal GnRH/LH levels are not affected by P234 [105]. P271 is a modified version of P234, with a penetrating sequence attached to enhance BBB permeability. P271 can inhibit the GnRH/LH surge induced by kisspeptin when administered systemically in rats and ewes [70, 106, 107]. Small molecule antagonists for KISS1R have also been synthesized via a 2-acylamino-4,6-diphenylpyridine scaffold [108]. Compound 15a, a minor molecule KISS1R antagonist, modified from compound 91, is designed with further optimization by containing a piperazine ring that enhances BBB permeability [109]. Compound 15a exhibits similar binding affinity and lower inhibition ability for KISS1R in vitro and in vivo in male rats compared to P234 [109]. Unlike peptide 234, which needs to be given by injection, compound 15a is a small molecule antagonist that is likely to facilitate oral administrationand is more applicable for clinical trials.

Dhillo et al. (2007) investigated the effects of KP54 intravenous administration in healthy women and found that the elevation of plasma KP54 levels significantly increased circulating LH, FSH, and testosterone levels [75]. Two years later, the same research group investigated the effects of a subcutaneous bolus injection of different doses of KP54 in healthy women and demonstrated that KP54 induced a dose-dependent (at doses from 0.2–6.4 nmol/kg) increase in LH release in all phases of the menstrual cycle, with the greatest effect in the preovulatory phase and least in the follicular phase of the cycle [50]. The ability of kisspeptin (KP54 and KP10) to stimulate gonadotropin secretion in healthy women is further confirmed in later studies [51‐55]. Interestingly, intravenous injection of KP10 at doses up to 10 nmol/kg induced elevated serum gonadotropins in women during the preovulatory phase but not in women during the follicular phase of the menstrual cycle [51]. Another two studies demonstrated that KP10 stimulated LH secretion in women regardless of the menstrual cycle phase [57, 58]. One possible explanation for the inconsistency towards the effects of KP10 on women during the follicular phase is that the stimulation of KISS1R in GnRH neurons in the early follicular phase is close to saturation. Thus the treatment of additional kisspeptin has little or no effect [57]. Another explanation is that the gonadotropin response to KP10 is directly and positively related to serum estrogen levels which is much higher during the preovulatory phase than the follicular phase [54, 55]. A recent study investigated the effect of kisspeptin in young, middle, and older men and found that the response of GnRH/LH secretion to kisspeptin stimulation is preserved across life [111]. TAK-448 and TAK-683 are two KP10 analogs initially used in patients with prostate cancer [93, 99]. A recent study demonstrated that healthy women in the follicular phase treated with TAK-448 showed a similar amplitude of LH rise compared with the treatment of KP54, but the peak of LH was much later with correspondingly increased area under the curve of LH exposure [67]. The results suggest a considerable therapeutic potential of TAK-448 in female reproduction.

The change of the number of LH pulses after a bonus administration of kisspeptin in healthy women is inconsistent, with one study showing a significantly increased mean number of LH pulses [52] and another study that showed no changes [57]. While the infusion of KP54 in healthy women does not abolish the menstrual cyclicity, it leads to a reduced length of the menstrual cycle and an earlier onset LH surge [53]. Additionally, continuous infusion of KP10 restores gonadotropin pulsatility in patients with impaired GnRH secretion caused by the loss-of-function mutations in NKB or NK3R, suggesting that KP10 is sufficient to stimulate pulsatile GnRH secretion on its own [48].

Continuous exposure to GnRH or its analogs suppress gonadal functions, leading to desensitization of GnRH receptor [112, 113]. Whether long-term treatment of kisspeptin can induce tachyphylaxis in humans remains discussion. Tachyphylaxis of LH response has been seen in women with hypothalamic amenorrhea who received twice-daily subcutaneous injections of KP54 (6.4 nmol/kg) for two weeks [63, 64]. Serum LH and FSH were increased significantly after kisspeptin injection and reduced to the baseline level on day 14 [63, 64]. However, twice-daily subcutaneous injections of KP54 (6.4 nmol/kg) for one week or subcutaneous infusion of KP54 (0.1–1.0 nmol/kg/h) for 8 hours did not cause tachyphylaxis of LH response in healthy women [53, 54]. Similarly, continuous infusion of KP10 (4 μg/kg/h) for 22.5 hours in healthy men increased LH secretion progressively with no observation of desensitization [77], whereas subcutaneous infusion of TAK-448 (0.01–1 mg/man/day) or TAK-683 (0.01–2 mg/man/day) for two weeks in healthy male volunteers resulted in acute stimulation of FSH/LH followed by suppression during continuous exposure [93, 99]. These studies collectively indicate that a two-week time is required to induce tachyphylaxis in both men and women. Additionally, as tachyphylaxis is seen in women with hypothalamic amenorrhea but not healthy women, whether the status of hypothalamic amenorrhea affects tachyphylaxis remains unclear. Because chronic administration of kisspeptin is implicated as a potential novel therapy in contraception or the treatment of hormone-sensitive cancer through inhibiting reproductive hormone secretion due to tachyphylaxis, whether long-term administration of kisspeptin can induce tachyphylaxis and what is the requirement for that in humans are of considerable importance and should be confirmed in the future.

In postmenopausal women, the ovary cannot respond to the pituitary hormones (FSH and LH) due to the depletion of ovarian follicles. While the ovarian estrogen and progesterone production ceases and the negative feedback from the ovary is absent, the HPO axis remains intact in these women. Current evidence regarding the effect of kisspeptin on gonadotrophin secretion in postmenopausal women remains controversial. One trial demonstrated that gonadotrophin response to KP10 in these women was enhanced when compared with women in the follicular phase (George, Anderson, and Millar 2012), whereas another trial found intravenous bolus of KP10 at the same doses (0.3 μg/kg) did not affect LH or FSH secretion [56]. Therefore, the effect of kisspeptin on gonadotrophin secretion in postmenopausal women should be further confirmed.

PCOS is a complex disorder involved with reproductive, metabolic, and endocrine disturbances in women of reproductive age. The characteristics of PCOS include polycystic ovaries morphology, olio-anovulation, and the presence of clinical and biochemical hyperandrogenism [114]. The observation of elevated LH-pulse frequency and perturbed LH/FSH ratio in women with PCOS implied the involvement of abnormal HPO axis in PCOS [115‐117]. Kisspeptin treatment leads to a similar increase of LH secretion in women with PCOS when compared with that in healthy women, and the LH pulse frequency is not changed [61, 62, 67], indicating that exogenous kisspeptin administration is not able to change the LH pulse frequency. Because NKB/NK3R pathway can promote kisspeptin secretion in the KNDy neuron, NKB antagonist administration may negatively regulate kisspeptin production and subsequently reduce GnRH/LH secretion. Indeed, previous studies demonstrated that the NK3R antagonist could reduce LH and testosterone secretion and slow LH pulse frequency in women with PCOS [62, 118]. Furthermore, LH response to kisspeptin is positively associated with estrogen concentrations [54, 55], but the positive correlation is abolished after NK3R antagonist treatment [62]. These data indicate a crucial role of the NKB component of the KNDy neuron in modulating the effect of the negative feedback of estrogen and the precise regulation of LH secretion.

HA is characterized by the cessation of menstruation due to deficient pulsatile secretion of GnRH [119]. The absence of pulsatile GnRH secretion leads to reduced circulating gonadotropins, reduced developing follicles, low estradiol levels, and cycle disturbances [120]. Therefore, restoring pulsatile GnRH secretion is likely to be an effective treatment for HA. Gonadotrophin response to kisspeptin administration is more advanced in women with HA than in healthy women or women with PCOS [67]. Acute administration of KP54 to women with HA significantly increases gonadotrophins secretion and LH pulsatility [63‐67], whereas chronic administration of KP54 at a dose of 6.4 nmol/kg twice daily for two weeks induces complete desensitization to its effects on gonadotropin release [63, 64]. In response to tachyphylaxis induced by long-term treatment of kisspeptin, Jayasena, et al. investigated the effect of administration of KP54 at a dose of 6.4 nmol/kg twice weekly for eight weeks on gonadotropin release. They demonstrated that women with HA remained partially sensitive to KP54 treatment during the first two weeks, and gonadotrophin responses to KP54 treatment did not significantly decrease beyond this initial two-week period [64]. However, this protocol of KP54 treatment could not restore menstrual cyclicity in women with HA during the eight weeks [64]. Furthermore, the number of follicles, the maximum size of the follicles, and the ovary volume were not increased in this protocol, indicating that this protocol is not therapeutic for HA. Further work is required to explore an effective protocol of kisspeptin administration that avoids tachyphylaxis and restores menstrual cyclicity and promotes the development of follicles in women with HA.

Idiopathic hypogonadotropic hypogonadism (IHH) is characterized by hypogonadism with low gonadotropins levels and sex steroids and absence of secondary sexual characteristics due to either pituitary or hypothalamic dysfunction [121]. As reported in previous studies, known genetic mutations account for about 30–50% of all IHH cases [122]. The majority of these genes encode proteins involved in the development and migration of GnRH neurons, regulation of GnRH secretion, and GnRH action in the pituitary [122]. GNRHR, TACR3, and KISS1R mutations are the most common mutations that lead to IHH [123, 124]. Around 10–22% of patients with IHH can recover reproductive endocrine function spontaneously [125, 126]. Exogenous pulsatile GnRH administration can serve as a powerful probe for pituitary function in IHH patients [127]. Similarly, kisspeptin, the primary upstream activator of the HPO axis, may be utilized as a potent probe for GnRH neuronal function in IHH patients. Indeed, pituitary response to GnRH is preserved in men with mutations of genes involved in the development and migration of GnRH neurons, but the pituitary response to kisspeptin is significantly attenuated when compared with healthy men (Abbara et al. 2021). Chan et al. recruited twelve patients (10 men and 2 women) with IHH (11 abiding IHH and 1 reversal IHH) who received intravenous boluses of kisspeptin (0.24 nmol/kg) before or after GnRH administration [128]. All patients with abiding IHH failed to induce LH pulse, whereas patients with reversal IHH showed robust response after exogenous kisspeptin administration. Based on this research, Lippincott et al. demonstrated that IHH patients with sustained reversal of their hypogonadotropism responded to kisspeptin and produced LH pulses, whereas IHH patients who had reversal but subsequently suffered a relapse of their IHH did not respond to kisspeptin [129]. The inability to respond to a physiologic dose of kisspeptin in IHH patients is observed in both estrogen-deficient and estrogen-replete states [130], indicating that the low estrogen level in IHH patients is not the underlying reason. This makes it possible to use kisspeptin as an adjunctive tool to assess for reversal in clinical practice. Nevertheless, not all patients with reversal IHH have a normal GnRH neuronal function because the reversal can occur even in patients with severe GnRH deficiency [126]. Therefore, these patients (reversal IHH with abnormal GnRH neuronal function) are unlikely to be accurately assessed for reversal by kisspeptin. Because most trials on IHH patients focus on men rather than women, future trials should also investigate whether the effect of kisspeptin in IHH patients shows the sexual difference.

The HPO axis is active during fetal life, with a peak between mid-gestation and subsequent decrease towards the end of pregnancy [131]. A further increase in gonadotropin secretion (sometimes called the ‘mini puberty of early infancy’) is observed among human infants, beginning at 1–2 weeks after birth and persisting for several months in male infants and ∼2 years in female infants [119, 132, 133]. HPO axis remains quiescent throughout childhood and then reactivates upon the onset of puberty [131]. Reactivation of the HPO axis with the reemergence of pulsatile GnRH release is the hallmark of puberty onset [134]. Animal studies demonstrated that KISS1R expression in the arcuate nucleus region increased significantly from the juvenile to mid pubertal stage, and repeated administration of kisspeptin or its analogs was able to advance puberty [89, 135‐139]. In humans, inactivating point mutations in KISS1R are associated with impaired pubertal development [13, 14]. Interestingly, mutation of the KISS1 gene that produces kisspeptins more resistant to in vitro degradation was reported in three unrelated patients with central precocious puberty [22]. These observations support the concept that the kisspeptin/KISS1R system is a therapeutic target to regulate the onset of puberty.

Central precocious puberty (CPP) is caused by the early reactivation of the HPO axis, with the development of secondary sexual characteristics before the age of 8 in girls and 9 in boys [140, 141]. In addition, several studies have shown that the level of serum kisspeptin increased significantly in CPP patients [142‐146], suggesting serum kisspeptin level can be used as a potential biomarker in diagnosing CPP.

For children (11 boys and 4 girls) with delayed puberty, a wide range of responsiveness to kisspeptin administration have been reported, with some showing a robust response (higher than 0.8 mIU/ml) and others showing little to no response [147]. The neuroendocrine profiles of the responders are similar to those of healthy adults. Meanwhile, those who lacked responses to kisspeptin presented similar neuroendocrine profiles to those adults with IHH [147].. If the diminished response to kisspeptin persists into adulthood, they will be found to have IHH. Thus, response to kisspeptin may be used to distinguish physiologic hypogonadotropic hypogonadism in normal prepubertal children from the pathological hypogonadotropic hypogonadotropism of children who have IHH. Interestingly, when these children reached the age of 18 years, those who responded to kisspeptin with LH rose higher than 0.8 mIU/mL subsequently progressed through puberty, and those who showed LH responses to kisspeptin less than 0.4 mIU/ml failed to develop puberty [148]. Therefore, responses to kisspeptin can also help to predict later pubertal development in children with delayed puberty.

IVF is a supraphysiological process that involves follicular maturation, ovulation triggering, fertilization, and embryo transfer. In this process, exogenous FSH is administered to induce the development of follicles in the ovary. Meanwhile, the GnRH receptor is downregulated by using the GnRH antagonist, or continuous treatment of a GnRH agonist to prevent an LH surge and premature ovulation. Once follicles grow to the requisite size, LH-like drugs are used to trigger ovulation [149]. Excessive exposure to LH-like drugs, such as human chorionic gonadotropin (hCG), recombinant LH (rLH), or GnRH agonist, can increase the risk of ovarian hyperstimulation syndrome (OHSS), which is an iatrogenic state that can lead to adverse consequences in women undergoing IVF treatment [150, 151]. Compared to hCG or rLH, which can directly activate the LH receptor in the ovary, GnRH agonist triggers ovulation by stimulating endogenous LH release from the pituitary, which is a more physiological process and has advantages in women with high risks of OHSS [152]. In recent years, kisspeptin has been used to induce ovulation in IVF treatment based on its ability to stimulate endogenous GnRH release and induce the subsequent LH surge. The first trial investigating kisspeptin administration to trigger ovulation was initiated in 2014 [59]. A single subcutaneous injection of KP54 was administered (1.6–12.8 nmol/kg) to induce the LH surge in women with subfertility, which resulted in a clinical pregnancy rate of 23% (12/53) and a live birth rate at 19% (10/54) [59]. Abbara et al. further explored the efficacy and safety of kisspeptin in inducing oocyte maturation in women at high risk of OHSS [153]. This study demonstrated that women treated 9.6 nmol/kg KP54 had the highest pregnancy rates (85%), and no woman developed moderate to severe OHSS [153]. The number of mature oocyte yields increased dose-dependently in both trials, indicating the variability in response in these women. A third trial was conducted to investigate whether a second dose of 9.6 nmol/kg KP54 at 10 hours following the first could result in efficacious oocyte maturation in women at high risk of OHSS [60]. This study showed the second dose of KP54 improved oocyte yield and resulted in a higher clinical pregnancy rate and live birth [60]. Notably, the rate of moderate to severe OHSS was not increased in women following a second dose of KP54 treatment. Interestingly, this study also found a pharmacodynamic effect of repeated dosing of KP54 [60]. The LH response to the second dose was likely to result from the LH response to the first KP54 bolus treatment. Women who showed a substantial LH response to the first dose had a lower LH rise following the second dose of KP54 and vice versa [60]. Therefore, the second dose of KP54 can restore and prolong the LH rise in women with a lower rise in LH following the first dose, leading to a reduced proportion of women with fewer than four oocytes yield [60]. This pharmacodynamic effect can be explained by the remaining hypothalamic GnRH stores in women with a lower rise in LH, thus allowing the second dose of KP54 to restore LH rise. In humans, hCG has a long half-life with peak serum levels at around 18 hours after injection. A peak serum LH is observed around 4 hours after injection of GnRH agonist [154] and 4 to 6 hours after injection of KP54, with a lower amplitude of LH following KP54 injection than that following GnRH agonist injection [149]. Compared to hCG and GnRH agonist for final oocyte maturation, triggered with kisspeptin leads to smaller median ovarian volume, lesser mean ascetic volumes, and least frequent OHSS symptoms in women at high risk of OHSS [155]. These data suggest that kisspeptin induces LH rise more physiologically when compared with the current protocol for oocyte maturation, particularly in women at high risks of OHSS. Importantly, injection of KP54 for final oocyte maturation is not feasible in women with an impairment in hypothalamic GnRH neuronal function. Additionally, while KP54 induces an LH surge sufficient for oocyte maturation, the duration of LH exposure is much shorter than that in hCG treatment, which may lead to the insufficient luteinizing of corpora luteal as seen in women treated with GnRH agonist [149]. Thus, adequate luteal phase support may be necessary to maintain the pregnancy rate in women triggered by KP54, and trials investigating whether the “double” or “dual” trigger by kisspeptin and hCG results in higher pregnancy rates when compared with the trigger by kisspeptin alone are of great interest.